date 2026-09-17 (day) read as 2026-09-16 (day, businesswire.com)
The company's Business Wire release states the round was announced on September 16, 2026, and identifies Forbion as lead, with participation from TPG Life Sciences Innovations and Sectoral Asset Management. The WSJ article was published September 17, 2026, but that later byline does not override the company's announcement date; no source states the company's headquarters, and the Business Wire dateline is not treated as headquarters evidence.
[ BUILT WITH ]·[ SEARCH ]found by Firecrawl search: announces "Series B" funding round led by·[ SCRAPE ]8 pages read: news.crunchbase.com, techstartups.com, tradersunion.com·[ JSON ]round extracted with a schema, grounded to one sentence·[ VERIFY ]correctedread back across 8 sources by gpt-5.6-luna·[ BRANDING ]logo and colour from the homepage·[ ALEXANDRIA ]firmographics from FullEnrich via Alexandria
date 2026-09-17 (day) read as 2026-09-16 (day, businesswire.com)
The company's Business Wire release states the round was announced on September 16, 2026, and identifies Forbion as lead, with participation from TPG Life Sciences Innovations and Sectoral Asset Management. The WSJ article was published September 17, 2026, but that later byline does not override the company's announcement date; no source states the company's headquarters, and the Business Wire dateline is not treated as headquarters evidence.
[ BUILT WITH ]·[ SEARCH ]found by Firecrawl search: announces "Series B" funding round led by·
Profile
[ ENRICHED ]
Does
Sling Therapeutics sells an oral therapy called linsitinib, targeting thyroid eye disease for patients.
Headcount
11
Type
Privately Held
Industry
Biotechnology
Via Alexandria from FullEnrich: headcount, type, industry
